


Biofilms & Urinary Tract Infections... A Sticky Situation

Kelly E. O'Neill, DVM

Mary Anna Labato, DVM, DACVIM

Linda Ross, DVM, DACVIM

Tufts University



You have asked...
What is a biofilm, and how does it affect
the urinary tract of animals?

The experts say...

A biofilm is a structured community of bacterial, fungal, or other cells enclosed in a self-produced polymeric matrix adherent to an inert or living surface.¹ Biofilms are common in living organisms, including animals, but can also be found in other environments. Biofilms alter the function and pathogenicity of bacteria. Growing evidence suggests they may play a substantial role in infections, especially those that are recurrent or difficult to treat.²

From the perspective of bacteria, becoming part of a biofilm confers certain advantages. Within the biofilm, bacteria are able to pool their resources and receive protection from the immune system, antimicrobials, harsh environments and other stressors. However, being part of a community may also decrease access to water and oxygen, especially at depths further from the surface, and lead to an accumulation of waste products.³ Adjusting to these disadvantages may ultimately enable bacteria to thrive in this environment and increase problems for veterinary patients.

Bacteria change from free-living (or planktonic) organisms to ones that can adhere to surfaces (ie, to establish a colony) in order to form a biofilm; in doing so their behavior and structure alter. As the community grows, autoinducers, chemical-signaling molecules that enable bacteria to sense one another and regulate one another's activities, accumulate. As they accumulate, the autoinducers induce changes in bacterial surface attachments, the extracellular polymeric matrix, and the amount and type of virulence factors that are expressed. Alterations in gene expression lead to phenotypic changes in flagella, the structure of cell walls, and the production of enzymes. Up to 40% of cell wall proteins appear to be different in bacteria found in a biofilm compared with their planktonic counterparts.⁴

MORE ►

From the perspective
of bacteria, becoming
part of a biofilm confers
certain advantages.

Most of what we know about the interactions between antimicrobials and bacteria are based on planktonic bacteria. However, biofilm bacteria can be up to 1000 times more resistant to antimicrobials than bacteria that are free-living.⁵ Antimicrobials may not penetrate deeply into the extracellular matrix or may be thwarted by the anaerobic interior. Increased antibiotic resistance develops because the proximity of bacteria increases their ability to share resistance genes with each other. In addition, at any time 1% to 10% of cells within a biofilm slow down because of altered metabolism and expression.⁵ Dormant cells exhibit a slower metabolism and are more resistant to antimicrobials. Dormancy is reversible, and when environmental changes occur, these cells can revert to a more active form.⁵

How Biofilms Affect the Urinary Tract

In a healthy animal, the lower urinary tract has many natural defenses that prevent the development of infections. Periodic emptying of the bladder, sloughing of epithelial cells that line the urinary system, and the mucous layer lining the epithelium prevent bacteria from staying in the urinary system. The body's natural immune response, low availability of iron (which is necessary for bacteria to function), and high concentration of urea also make the urinary system inhospitable to bacteria.⁶

Alterations in the normal structure of the lower urinary tract, however, can make it easier for bacteria to adhere, grow, and create a probiofilm environment. Any event that causes trauma to the mucosal layer of the bladder and erodes the glycosaminoglycan layer can result in a disruption in these natural defenses.


Alterations in the normal structure of the lower urinary tract, however, can make it easier for bacteria to adhere, grow, and create a probiofilm environment. Any event that causes trauma to the mucosal layer of the bladder and erodes the glycosaminoglycan layer can result in a disruption in these natural defenses.

Such events include placement of a urinary catheter, the presence of stones, or masses within the bladder or urethra. In animal models of urinary tract infections (UTIs), bacteria instilled directly into the bladder of healthy animals were cleared in 2 to 3 days by natural mechanisms. However, the presence of a surgically placed foreign object in the bladder caused animals to develop chronic urinary tract infections with a concurrent biofilm on the foreign object in less than 24 hours.⁷

Recognizing Biofilms

Biofilms tend to develop in the urinary tract—but how do we detect the presence of a biofilm?

Unfortunately, biofilms are difficult to



Staphylococcus aureus biofilm on an indwelling catheter

detect. Visualization techniques used in research include scanning electron microscopy or confocal laser microscopy, neither of which is readily available or useful to detect infection in a live animal. A polymerase chain reaction (PCR) test to search for a biofilm-specific gene is in development but is not yet commercially available.⁸

Suspect the presence of a biofilm under the following conditions:

- Any chronic urinary tract infection, especially when the patient presents with a low bacterial cell count.
- Relapses occur after theoretically successful treatment.
- Antibiotic use fails to clear signs in culture-directed treatment.
- Any catheter-associated infection.^{5,9} While a foreign object is not necessary, the presence greatly increases the likelihood of biofilm development.
- Urine culture is negative but the patient responds to antimicrobial treatment.

Treatment

If a biofilm infection is suspected, treatment strategies include prompt removal of implants or foreign material in combination with appropriate antimicrobial therapy. There is no perfect treatment

PCR = polymerase chain reaction, UTI = urinary tract infection

If a biofilm infection is suspected, treatment strategies include prompt removal of implants or foreign material in combination with appropriate antimicrobial therapy.

strategy, but options include prolonged antibiotic use (≥ 6 weeks [this is a highly empirical therapy unsupported by clinical evidence]), higher antibiotic dosages, and using a combination of antibiotics.^{6,9} Research suggests that β -lactams and aminoglycosides may help prevent the formation of a biofilm but are less useful once a colony has become established; fluoroquinolones, on the other hand, are better able to penetrate an “older” biofilm colony (ie, a well-established colony that may have secondary bacteria communities and decreased frequency of dividing and growing).¹ Although there is no clinical evidence to support their effect on the biofilm, the instillation of commensal bacteria shows promise in the treatment of some infections (eg, commensal strains of *Staphylococcus epidermidis* that secrete the EspA protease to prevent biofilm formation and nasal colonization by *S aureus* in humans). These low-virulence bacteria cause passive interference with more pathogenic strains, and this strategy has shown success in human cases of recurrent UTI and vaginitis (eg, with *Lactobacillus* spp).^{4,10}

Research in human medicine is exploring potential strategies that may prove useful in eliminating these infections, including strategies to induce the dissolution of biofilms and the use of low-energy surface acoustic waves to disrupt biofilm formation. Research is under way to investigate drugs that target biofilm-

specific enzymatic activity and promote dispersion signals to break up biofilms to increase susceptibility to antimicrobial therapy.^{1,9}

Prevention

One of the most successful strategies in the fight against biofilms is aggressive prevention. Utilizing best practices when placing and maintaining indwelling urinary catheters can decrease infection rates. Indwelling catheters should be avoided when possible, and staff should be encouraged to consistently follow general recommendations to eliminate microorganism migration. These recommendations include washing hands with antiseptic soap for at least 30 seconds or using alcohol-based hand rubs between patients if water is not available.¹¹ In addition, it is critical to avoid contamination when manipulating catheter connection sites. Catheters that become infected or soiled should be replaced immediately.⁵ Despite these strategies, rates of catheter-associated UTIs remain high.¹²

Biofilms can contribute to chronic infections, and treatment of these infections can be challenging. In the future, new treatment modalities may offer options for preventing and eliminating biofilms.

■ **cb**

See **Aids & Resources**, back page, for references & suggested reading.

quellin™ (carprofen)

soft chewable tablets

Non-steroidal anti-inflammatory drug
For oral use in dogs only

BRIEF SUMMARY:

Before using quellin soft chewable tablets, please consult the product insert, a summary of which follows:

CAUTION: Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

PRODUCT DESCRIPTION: quellin (carprofen) is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen.

INDICATIONS: Carprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

CONTRAINDICATIONS: Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

WARNINGS: Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered.

PRECAUTIONS: As a class, NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid. When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These antiprostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients. Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs, vents involving suspected renal, hematologic, and neurologic, dermatologic, and hepatic effects have also been reported. Concomitant use of carprofen with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Carprofen is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. The safe use of carprofen in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established.

ADVERSE REACTIONS:

During investigational studies for the caplet formulation with twice-daily administration of 1 mg/lb., no clinically significant adverse reactions were reported. Some clinical signs were observed during field studies which were similar for carprofen caplet and placebo treated dogs. Incidences were observed in both groups: vomiting (4%), diarrhea (4%), changes in appetite (3%), lethargy (1.4%), behavioral changes (1%), and constipation (0.3%).

For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

ANADA 200-555 Approved by FDA

©2014 Bayer HealthCare LLC. Bayer (reg'd), the Bayer Cross (reg'd), quellin™ are trademarks of Bayer.

Bayer HealthCare LLC, Animal Health Division, PO Box 390,
Shawnee Mission, KS 66201 GHG060514
January 2014 18827